- The data includes results from P-III extension studies of OPERA I, OPERA II and ORATORIO assessing Ocrevus in patients with RMS and PPMS earlier treated with IFN beta-1α or PBO respectively
- Ocrevus resulted in suppression of relapse and MRI disease (16.1% vs 21.3% @5yrs.), suppression of T1-gadolinium enhancing (T1-Gd+) lesions (0.004 vs 0.49 @3yrs.) in RMS; In PPMS patients DP reduced to 96% and upper limb DP is 13.4% as measured by the nine-hole peg test (9-HPT) @24 wks.
- Additionally, results from P-III CHORDS for RRMS showed no relapse, T1-Gd+ lesion MRI activity and N/E T2 lesion MRI activity with no 24-wks CDP @48wks. Ocrevus is approved in 68 countries including EU, Australia& Switzerland with awaited marketing approval in 20 countries
Click here to read full press release/article | Ref: Roche | Image: Roche Diagnostics